Research Strategy and Studies

A summary of our research strategy for 2015-2017 can be viewed by clicking here.

The list below shows current studies in the Academic Directorate of Respiratory Medicine. For further information please contact


  • CF – Cystic Fibrosis
  • COPD – Chronic Obstructive Pulmonary Disease
  • ILD – Interstitial Lung Disease
  • Inf / Imm - Inflammation & Immunity
  • PH – Pulmonary Hypertension
  • NIHR – National Institute for Health Research
Theme Principal Investigator Title Funder
Asthma Sabroe Screening of target genes for polymorphic variation which may alter treatment response for airway management
University of Nottingham
Asthma Sabroe Study of mechanisms of action of Omalizumab in severe asthma Novartis
Asthma Sabroe A 52-week, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma. Novartis
Asthma Sabroe The control of innate immunity, host pathogen interactions, and leukocyte function in healthy volunteers Medical Research Council
CF Edenborough Cystic Fibrosis Registry Cystic Fibrosis Trust
CF Wildman Combination of lung MR imaging with physiological assessment to identify and monitor ventilation heterogeneity in early CF lung disease. Cystic Fibrosis Trust
CF Wildman Analysis of routinely collected clinical data to support quality improvement of an adult CF centre. STH Directorate
CF Wildman Hyperpolarised gas MRI and multiple breath inert gas washout to improve management and understanding of cystic fibrosis lung disease. NIHR Fellowship (Laurie Smith)
CF Wildman Quality of life measurement in people with cystic fibrosis registered with the UK CF Registry Cystic Fibrosis Trust
CF Wildman CF Health Hub Data Observatory NHS England
CF Wildman Development and evaluation of an intervention to support Adherence to treatment in adults with Cystic Fibrosis: A randomised controlled trial and parallel process evaluation NIHR
CF Wildman A study of how patients with Cystic Fibrosis in the UK interpret and respond to the PAM-13 NIHR Programme Grants
COPD Hughes A Randomized, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of PT009 compared to PT005 on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD AstraZeneca UK
COPD Lawson A randomized, double-blind, placebo-controlled, two-period crossover study to assess the effect of inhaled QVA149 on global and regional lung function and gas exchange in patients with moderate to severe COPD Novartis
COPD Lawson Lung magnetic resonance Imaging with FluorocarbonTracer gases MRC
ILD Bianchi The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary Fibrosis with the addition of Co-trimoxazole (EME-TIPAC) NIHR EME
ILD Bianchi A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib co-administered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment Boehringer Ingelheim Ltd
ILD Renshaw Identification of disease susceptibility genes and autoantibodies associated with the development and clinical characteristics of interstitial lung disease (ILD) in patients with and without proven connective tissue diseases (CTDs). University of Liverpool
ILD Bianchi Multi-center, international, double-blind, two-arm, randomized, placebo-controlled phase II trial of pirfenidone in patients with unclassifiable progressive fibrosing ILD Hoffman-La Roche
ILD Bianchi Investigation into prognostic indicators of Idiopathic Pulmonary Fibrosis using structural-functional pulmonary MRI assessment University of Sheffield
ILD Bianchi Functional MRI and PETCT in Idiopathic Pulmonary Fibrosis Hull + EY NHS Foundation Trust
Meso Lewis Randomised controlled trial to compare the diagnostic yield of Positron Emission Tomography Computed Tomography TARGETed pleural biopsy versus CT guided pleural biopsy in suspected pleural malignancy North Bristol NHS Trust
PH Condliffe Long term, multicenter, single-arm, open-label extension study of the MERIT-1 study, to assess the safety, tolerability and efficacy of macitentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) merit Actelion Pharmaceuticals
PH Kiely What is the effect of intravenous iron supplementation on exercise capacity and quality of life in patients with IPAH and iron deficiency? FERINJECT British Heart Foundation
PH Kiely Sheffield Pulmonary Hypertension Biobank British Heart Foundation
PH Kiely National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension Medical Research Council
PH Kiely A randomized, double-blind, placebo-controlled, prospective, multicenter, parallel group study to assess the safety and efficacy of macitentan in patients with portopulmonary hypertension (PORTICO) Actelion Pharmaceuticals
PH Kiely A prospective, multicenter, single-arm, open-label, Phase 4 study to evaluate the effects of macitentan on Right vEntricular remodeling in Pulmonary ArterIal hypeRtension assessed by cardiac magnetic resonance imaging - REPAIR Actelion Pharmaceuticals
PH Kiely TRANSFORM-UK: A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension NIHR
PH Kiely Assessing the Spectrum of Pulmonary Hypertension In a Referral Centre (ASPIRE) STH Pulmonary Vascular Disease Unit
PH Kiely Pilot study: Use of Functional MRI to understand the pathophysiology of abnormalities of gas exchange in patients with idiopathic pulmonary fibrosis and systemic sclerosis University of Sheffield
PH Kiely Investigation into predictors of diagnosis in PAH patients IMS Health
PH Kiely International CTEPH Registry Actelion Pharmaceuticals
Resp Peachell Sheffield Lung Research Tissue Bank Novartis

For further information please contact